ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pfizer’s chief scientific officer, Mikael Dolsten, is slated to depart after 15 years at the drug giant. Dolsten will remain in the role while a successor is identified, which Pfizer says could take until early 2025. Dolsten joined Pfizer when it acquired Wyeth in 2009. He was promoted to the executive suite shortly after and went on to oversee the approval of more than 35 drugs and vaccines, including Pfizer’s vaccine and therapy for COVID-19. Dolsten has not indicated his next move but wrote on LinkedIn that he wants to “contribute to the next wave of breakthroughs in exciting, new ways.”
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X